NEW YORK, Oct. 1 - Rubicon Genomics yesterday said it has secured $3.5 million in a Series B round of private-equity funding.
The Ann Arbor, Mich.-based company said it will use the cash to commercialize its OmniPlex technology. The round brings to $7.2 million Rubicon has pocketed since it was founded in 2000.
ARCH Development Partners led the round. Picking up the rear were Duchossois TECnology Partners, Sloan Ventures, and undisclosed individual investors.
Rubicon said OmniPlex is designed to allow researchers with a particular focus on diagnostics to amplify, archive, and analyze DNA.
Click here for more information.